Jacobiopharma
Jacobio Pharmaceuticals is a pharmaceutical company.
Jacobiopharma, founded in July, 2015 and headquartered in Beijing, is an innovative drug development and solution provider. Established by Wang Yinxiang, the company has received financings from Qiming Venture Capital, Liyi Investment, Fluence Bioengineering and so on. Rivals that have direct and indirect competition with Jacobiopharma globally include Qiyu Bio, etc.
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ForLong Biotech Nets Over CNY 100 Mn in Series A
4 Chinese Immunotherapy Companies to Keeps Tabs on in 2019
Four Chinese pharmaceuticals are developing promising cancer immunotherapy drugs. Along with the advantageous policies and unmet needs within China's healthcare ecosystem, they will presumably shine for patients and investors in 2019.
May 15, 2019 02:34 PM
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Levostar Completes Pre-A Financing Round to Further Invest in CGT
BlissBio Nets Over CNY 100 Mn in Series B+
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
NaviSeed Nets Tens of millions of CNY in Angel Round
Nuwacell Nets Hundreds of Mns of CNY in Series A
Biotech in China: Oasis in the Desert?
Following AstraZeneca's USD 1 billion-large capital injection plans with China's state-backed CICC, and I-Mab Biopharma's long-anticipated IPO, all eyes are back on China's lucrative Biotech scene. EqualOcean sums up the story.
Nov 12, 2019 06:02 PM
'The Great Globalization Forward' Continues in China's CRO Scene: dMed Secures New Round
Qiming-backed dMed Biopharma undertook its Series B funding round worth USD 55 million led by Vivo Capital. The transaction represented yet another funding in China's rising CRO industry stemming from the newly-drafted NMPA policies.
Oct 19, 2019 02:10 PM
Enitiatebio Nets One Hundred Million of CNY in Series A Round
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
Ascletis Pharma’s Annual Report: CNY 154 Million Gross Profits
Ascletis released its 2018 Annual Report. According to the report, the total revenue of the company is CNY 166 million, a year-on-year increase of 212.6%; the gross profit of around CNY 154 million, an increase of 189.4%.
Apr 25, 2019 07:52 PM
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange